Overall survival among chemotherapy-naïve castration-resistant prostate cancer patients under abiraterone versus enzalutamide: a direct comparison based on a 2014-2018 French population study (the SPEAR cohort) - Centre Eugène Marquis Accéder directement au contenu
Article Dans Une Revue American Journal of Epidemiology Année : 2021

Overall survival among chemotherapy-naïve castration-resistant prostate cancer patients under abiraterone versus enzalutamide: a direct comparison based on a 2014-2018 French population study (the SPEAR cohort)

Résumé

Abiraterone acetate (ABI) and enzalutamide (ENZ) are considered to be clinically relevant comparators among chemotherapy-naive patients with castration-resistant prostate cancer. No clinical trials comparing overall survival with ABI versus ENZ in a head-to-head approach have been published so far. A few observational studies with low power suggested a potential benefit of ENZ. We used the French National Health Data System to compare overall survival of new users of ABI and ENZ among chemotherapy-naive patients with castration-resistant prostate cancer in 2014-2017, followed through 2018 (the SPEAR cohort, a 2014-2018 cohort study). With an intent-to-treat approach, a survival analysis was performed, estimating hazard ratios for overall survival with the inverse probability weighted Cox model method. Among 10,308 new users, 64% were treated with ABI and 36% with ENZ. The crude mortality rate was 25.2 per 100 person-years (95% confidence interval (CI): 24.4, 26.0) for ABI and 23.7 per 100 person-years (95% CI: 22.6, 24.9) for ENZ. In the weighted analysis, ENZ was associated with better overall survival compared with ABI (hazard ratio = 0.90 (95% CI: 0.85, 0.96) with a median overall survival of 31.7 months for ABI and 34.2 months for ENZ). When restricting to 2015-2017 new users, the effect estimate shifted up to a hazard ratio of 0.93 (95% CI: 0.86, 1.01).
Fichier principal
Vignette du fichier
Scailteux_et_al_Overall_survival_among_chemotherapy_accepted.pdf (316.8 Ko) Télécharger le fichier
Scailteux_et_al_Overall_survival_among_chemotherapy_suppl_data.pdf (604.96 Ko) Télécharger le fichier
Origine : Fichiers produits par l'(les) auteur(s)

Dates et versions

hal-02959030 , version 1 (26-11-2020)

Identifiants

Citer

Lucie-Marie Scailteux, Boris Campillo-Gimenez, Sandrine Kerbrat, Fabien Despas, Romain Mathieu, et al.. Overall survival among chemotherapy-naïve castration-resistant prostate cancer patients under abiraterone versus enzalutamide: a direct comparison based on a 2014-2018 French population study (the SPEAR cohort). American Journal of Epidemiology, 2021, 190 (3), pp.413-422. ⟨10.1093/aje/kwaa190⟩. ⟨hal-02959030⟩
935 Consultations
720 Téléchargements

Altmetric

Partager

Gmail Facebook X LinkedIn More